Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Chuan Gu, Xiaodong Zhang et al.|The Lancet Respiratory Medicine|2022Cited by 235
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Chuan Gu, Gongyan Chen et al.|Journal of Thoracic Oncology|2022Cited by 79
First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).Yuankai Shi, Fenlai Tan, Lin Wang et al.|Journal of Clinical Oncology|2016Cited by 14
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerYuankai Shi, Nan Ge, Gongyan Chen et al.|The Lancet Regional Health - Western Pacific|2024Cited by 7